Hey readers! This week's headline finding sounds alarming at first glance, but the numbers tell a more reassuring story than the framing suggests. We'll unpack the celiac-transplant link, then round up drug pipelines, labeling wins, and a few practical notes for living gluten-free.

🫁 The transplant study, in context

Celiac Disease Linked to Higher Risk of Liver and Kidney Transplants in New Study (+Video) reports on a nationwide Swedish cohort of 41,277 people with biopsy-confirmed celiac disease, showing a statistically significant increase in the relative risk of solid organ transplantation versus matched controls.
Celiac.com

Here is the crucial nuance for anyone whose stomach just dropped: the absolute risk stayed low. About two out of every one thousand people with celiac disease received a transplant during follow-up, and the raw counts were close between the two groups.

During the follow-up period, 85 people with celiac disease received a solid organ transplant, compared with 111 people in the matched comparison group.

The clearest signal was with liver transplantation, with kidney transplants also more common; heart transplants were rare and not clearly increased. The study could not prove causation, and it lacked detailed data on gluten-free diet adherence. Notably, researchers found no clear difference in transplant risk between people whose intestinal lining healed and those with persistent damage, but they reaffirmed that a strict gluten-free diet remains the established treatment. Bottom line for practitioners and patients: worth awareness, not alarm.

💊 Drug pipelines worth watching

Several autoimmune programs with celiac tracks moved this month, most centered on IL-15, the cytokine driving the immune response in celiac tissue.

Teva's Anti-IL-15 Antibody Advances Vitiligo covers Phase Ib vitiligo data for TEV-'408, which also carries a celiac development track with US FDA Fast Track designation granted in May 2025 and a Phase IIa study underway.
– AllSci

TEV-'408 blocks IL-15, a cytokine that drives the autoimmune destruction of melanocytes in vitiligo by activating cytotoxic CD8+ T cells.

Per Clinical Trials Arena, Teva's celiac Phase IIa readout is planned for the second half of 2026, so we may hear more soon.

"We wanted to explore gut bacteria because their abundance differs between healthy people and patients with celiac disease," said Dhiraj Dhotre, a scientist at NCCS and the study's corresponding author.

🏷️ Labeling and advocacy

Good news on the policy front, especially for anyone who has squinted at an ingredient list wondering about barley or rye.

FAO/WHO Codex Alimentarius Commission Adopts Science-Based Guidance for Precautionary Labeling of Cereals Containing Gluten establishes, for the first time, a 4 mg reference dose for cereals containing gluten while preserving the existing 20 ppm gluten-free standard.
– Celiac Disease Foundation

For the first time, there is a reference dose for cereals containing gluten, an important milestone for the celiac disease community, and one that the Celiac Disease Foundation worked over the last two years to make possible.

The Association of European Coeliac Societies welcomed the same Codex agreement, stressing that a product requiring a precautionary "may contain" statement should not simultaneously carry a gluten-free claim.

👶 For families and clinicians

Why Children With Type 1 Diabetes Should Be Screened for Celiac Disease reviews a Saudi study of 407 children with type 1 diabetes in which 13.7% of those screened had positive celiac results, a strong argument for routine screening since symptoms can be subtle.
Celiac.com

🥗 A practical living note

While the science evolves, a strict gluten-free diet remains the only established treatment. When you're eating out or traveling, the Find Me Gluten Free site and app (https://www.findmeglutenfree.com/) is a genuinely handy way to scout safe restaurants and reviews from other celiac diners. We're not sponsored by them; it's just a tool a lot of people find useful.

That's the issue. Take care of yourselves, and we'll see you next time.

Keep reading